CN105101977A - 治疗心力衰竭的方法 - Google Patents

治疗心力衰竭的方法 Download PDF

Info

Publication number
CN105101977A
CN105101977A CN201480020281.5A CN201480020281A CN105101977A CN 105101977 A CN105101977 A CN 105101977A CN 201480020281 A CN201480020281 A CN 201480020281A CN 105101977 A CN105101977 A CN 105101977A
Authority
CN
China
Prior art keywords
nitrate
inorganic
heart failure
group
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480020281.5A
Other languages
English (en)
Chinese (zh)
Inventor
胡利奥·A·奇里诺斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
Original Assignee
University of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania filed Critical University of Pennsylvania
Publication of CN105101977A publication Critical patent/CN105101977A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201480020281.5A 2013-02-07 2014-02-07 治疗心力衰竭的方法 Pending CN105101977A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361761863P 2013-02-07 2013-02-07
US61/761,863 2013-02-07
PCT/US2014/015300 WO2014124256A1 (en) 2013-02-07 2014-02-07 Methods of treating heart failure

Publications (1)

Publication Number Publication Date
CN105101977A true CN105101977A (zh) 2015-11-25

Family

ID=51300154

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480020281.5A Pending CN105101977A (zh) 2013-02-07 2014-02-07 治疗心力衰竭的方法

Country Status (6)

Country Link
US (1) US20150366901A1 (cg-RX-API-DMAC7.html)
EP (1) EP2953631A4 (cg-RX-API-DMAC7.html)
JP (1) JP6441818B2 (cg-RX-API-DMAC7.html)
CN (1) CN105101977A (cg-RX-API-DMAC7.html)
CA (1) CA2900526C (cg-RX-API-DMAC7.html)
WO (1) WO2014124256A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6531990B2 (ja) * 2013-02-28 2019-06-19 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 心肺血行動態を改善するための無機亜硝酸塩
JP6971495B2 (ja) 2017-03-23 2021-11-24 ミッション ソルト インコーポレイテッド ビートルート含有組成物
US11324748B2 (en) 2017-04-21 2022-05-10 Northeast Ohio Medical University Vasodilators for treatment of heart failure
US10702796B2 (en) * 2017-09-13 2020-07-07 Thermolife International, Llc Enriched root powder products and methods of producing thereof
FI128489B (en) 2018-10-01 2020-06-15 Precordior Oy Equipment for generating information indicating cardiac abnormality

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101622005A (zh) * 2007-02-26 2010-01-06 乔恩·伦德伯格 亚硝酸根和硝酸根的新用途和包含它们的组合物
WO2012076667A1 (en) * 2010-12-08 2012-06-14 Solvotrin Innovations Limited Compounds for treatment of heart failure
US20120214818A1 (en) * 2009-09-11 2012-08-23 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
WO2012142413A2 (en) * 2011-04-14 2012-10-18 Theravasc Inc. Nitrite compositions and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004884A2 (en) * 2003-07-09 2005-01-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
WO2011056572A1 (en) * 2009-10-27 2011-05-12 The Board Of Trustees Of The University Of Illinois Methods of diagnosing diastolic dysfunction
JP6531990B2 (ja) * 2013-02-28 2019-06-19 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 心肺血行動態を改善するための無機亜硝酸塩

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101622005A (zh) * 2007-02-26 2010-01-06 乔恩·伦德伯格 亚硝酸根和硝酸根的新用途和包含它们的组合物
US20120214818A1 (en) * 2009-09-11 2012-08-23 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
WO2012076667A1 (en) * 2010-12-08 2012-06-14 Solvotrin Innovations Limited Compounds for treatment of heart failure
WO2012142413A2 (en) * 2011-04-14 2012-10-18 Theravasc Inc. Nitrite compositions and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SCOTT K. FERGUSON ET AL.: "Impact of dietary nitrate supplementation via beetroot juice on exercising muscle vascular control in rats", 《J PHYSIOL》 *
STEPHEN J. BAILEY ET AL.: "Dietary nitrate supplementation reduces the O2 cost of low-intensity exercise and enhances tolerance to high-intensity exercise in humans", 《J APPL PHYSIOL》 *
VIKAS KAPIL ET AL.: "Inorganic Nitrate Supplementation Lowers Blood Pressure in Humans-Role for Nitrite-Derived NO", 《HYPERTENSION》 *

Also Published As

Publication number Publication date
CA2900526C (en) 2021-05-04
WO2014124256A1 (en) 2014-08-14
US20150366901A1 (en) 2015-12-24
EP2953631A1 (en) 2015-12-16
JP2016507570A (ja) 2016-03-10
EP2953631A4 (en) 2017-03-01
CA2900526A1 (en) 2014-08-14
JP6441818B2 (ja) 2018-12-19

Similar Documents

Publication Publication Date Title
Papadia et al. Citrulline in health and disease. Review on human studies
Lobo Fluid, electrolytes and nutrition: physiological and clinical aspects
ES3003888T3 (en) Blood purification by alkalinizing agent
Khanna et al. The management of hyperkalemia in patients with cardiovascular disease
JP6441818B2 (ja) 心不全の治療法
JP2025118624A (ja) ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法
Stevens et al. Exercise improves cardiac function and attenuates insulin resistance in Dahl salt-sensitive rats
Strugaru et al. Metformin induced lactic acidosis–particularities and course
US20180140579A1 (en) Sacubitril and valsartan for treating metabolic disease
Xiang et al. Impaired blood pressure compensation following hemorrhage in conscious obese Zucker rats
CN105025891B (zh) Hmb和atp的组合物及使用方法
US20050153020A1 (en) Composition comprising phosphate
Lee-Chiong Jr et al. The heart in the stable COPD patient
Sirirat et al. Pharmacokinetics and pharmacodynamics of single dose of inhaled nebulized sodium nitrite in healthy and hemoglobin E/β-thalassemia subjects
US20200108090A1 (en) Composition of HMB and ATP and Methods of Use
Abdullah et al. Goal directed fluid optimization using pleth variability index versus corrected flow time in cirrhotic patients undergoing major abdominal surgeries
Dumler et al. Optimal dialysis for the end-stage renal disease patient with cardiovascular disease
MD et al. What the clinician needs to know about medical nutrition therapy in critically ill patients in 2023: A narrative review
Rekovets et al. INFLUENCE DIFFERENT TYPE OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION (AH) AND METABOLIC SYNDROME (MS) ON INSULIN RESISTANCE DEPENDS ON SEX: PP. 34.398
JP5477413B2 (ja) 分岐鎖アミノ酸の心不全適応
Efanov et al. ARTERIAL HYPERTENSION CONTROL IN THE EXTREME NORTH POPULATION OF THE EMPLOYABLE AGE: PP. 34.397
JP5076327B2 (ja) 分岐鎖アミノ酸の心不全適応
Gordillo et al. Disorders of sodium homeostasis
Ferrara et al. HIGH TG/HDL RATIO HELPS IN THE EVALUATION OF CV RISK OF HYPERTENSIVE PATIENTS WITHOUT METABOLIC SYNDROME: PP. 34.400
HK1217087B (en) Composition of hmb and atp and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151125

WD01 Invention patent application deemed withdrawn after publication